The predictive role of 24h RAIU with respect to the outcome of low fixed dose radioiodine therapy in patients with diffuse toxic goiter
Authors:
- Nishikant DamleNDNishikant Damle
- Chandrasekhar BalCBChandrasekhar Bal
- Praveen KumarPKPraveen Kumar
- Ramamohan ReddyRRRamamohan Reddy
- Deepali VirkarDVDeepali Virkar
- 1 October 2012
- journal article
- Published by Springer Nature in Hormones
- Vol. 11 (4) , 451-457
Abstract
Radioactive iodine uptake (RAIU) is a test used to differentiate hyperthyroidism from thyroiditis and to calculate the radioiodine dose for treatment of Graves' disease. We aimed to evaluate the predictive role of 24h RAIU with respect to the outcome of radioiodine therapy in patients with diffuse toxic goiter (DTG). Case records of patients with DTG treated with radioactive iodine were reviewed retrospectively. Patients were divided into two groups based on 24h RAIU (normal range: 15% - 35% at 24 h): the first group included patients with 24h RAIU values equal to or less than 50%, while the second group included patients with 24h RAIU values of over 50%. Gland size, duration of disease, treatment with antithyroid drugs (ATD) and its duration were the other factors considered. Success of the first dose of 131I was defined as a euthyroid or hypothyroid status at 12 months post-therapy without the need for additional radioiodine or ATD therapy. Data were analyzed with 95% power and 1% type I error (α=0.01). Six hundred thirty-three (633) consecutive patients with DTG were given a fixed-dose (5mCi) of radioiodine between January 1987 and December 2006. One hundred seventy-five patients (175) had an RAIU ≤50% and 458 patients had an RAIU >50%. First-dose success rate in the former group was 81.7% and in the second group 68.6% (p=0.001). The overall first-dose success was 72%. Multivariate analysis confirmed the significant role of 24h RAIU data to predict a successful outcome. A 24h RAIU value of ≤50% appears to be associated with a significantly better outcome compared to that of a 24h RAIU value of >50% in patients with DTG given as treatment a fixed dose of 185 MBq radioiodine.Keywords
This publication has 22 references indexed in Scilit:
- Radioiodine therapy and thyrostatic drugs and iodineEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- A Randomized Controlled Trial to Evaluate the Adjuvant Effect of Lithium on Radioiodine Treatment of HyperthyroidismThyroid®, 2002
- A theoretical model for prescription of the patient-specific therapeutic activity for radioiodine therapy of Graves$apos$ diseasePhysics in Medicine & Biology, 2002
- Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123IEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Reevaluation of the Impact of a Stringent Low-Iodine Diet on Ablation Rates in Radioiodine Treatment of Thyroid CarcinomaThyroid®, 2001
- Study of the Correlation between Administered Activity and Radiation Committed Dose to the Thyroid in 131I Therapy of Graves' DiseaseRadiation Protection Dosimetry, 2001
- Is thyroxine during lithium therapy necessary?Journal of Endocrinological Investigation, 1999
- Radioiodine Therapy for Graves' Disease: Case Selection and Restrictions Recommended to Patients in North AmericaThyroid®, 1997
- Treatment with Propylthiouracil before Radioactive Iodine Therapy Is Associated with a Higher Treatment Failure Rate Than Therapy with Radioactive Iodine Alone in Graves' DiseaseThyroid®, 1995
- The Management of HyperthyroidismNew England Journal of Medicine, 1994